Y-mAbs Therapeutics, Inc. Q2 2024 Earnings Call Transcript
| YMAB Stock | USD 9.77 0.24 2.40% |
About 67% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
YMAB |
Y-mAbs Therapeutics, Inc. Q2 2024 Earnings Call Transcript August 12, 2024Y-mAbs Therapeutics, Inc. misses on earnings expectations.
Read at insidermonkey.com
 |
Y MAbs Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Y MAbs Fundamental Analysis
We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Y MAbs is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Y mAbs Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.
Peers
Y MAbs Related Equities
| PASG | Passage Bio | 2.63 | ||||
| PCVX | Vaxcyte | 0.69 | ||||
| BDTX | Black Diamond | 0.79 | ||||
| KRON | Kronos Bio | 1.96 | ||||
| BLUE | Bluebird Bio | 2.56 | ||||
| DAWN | Day One | 2.66 | ||||
| MIRM | Mirum Pharmaceuticals | 3.05 | ||||
| RVMD | Revolution Medicines | 3.23 | ||||
| MRUS | Merus BV | 4.03 | ||||
| ARQT | Arcutis Biotherapeutics | 4.07 | ||||
| TVTX | Travere Therapeutics | 4.12 | ||||
| SNDX | Syndax Pharmaceuticals | 5.34 | ||||
| ERAS | Erasca | 5.40 | ||||
| EWTX | Edgewise Therapeutics | 5.54 | ||||
| LRMR | Larimar Therapeutics | 6.00 | ||||
| GBIO | Generation Bio | 6.30 | ||||
| CCCC | C4 Therapeutics | 8.28 | ||||
| STRO | Sutro Biopharma | 10.20 | ||||
| ZNTL | Zentalis Pharmaceuticals | 10.57 | ||||
| MRSN | Mersana Therapeutics | 14.18 |
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |